Vaccination

Innovative Antibody Discovered by RQ Bio Enters Clinic as Part of Antibody Combination Within 12 Months of Discovery

Retrieved on: 
Wednesday, December 21, 2022
Antibody, Vaccination, Patient, AstraZeneca, Omicron, COVID-19, Risk, Safety, Death, Degenerative disease, Fry, Vaccine, Ministry of Women and Vulnerable Populations, Pre-exposure prophylaxis, Pharmaceutical industry

The potential for rapid impact on patients is a hallmark of the RQ Bio discovery process, which stretches across four key disease areas of huge patient need, including COVID-19 and influenza.

Key Points: 
  • The potential for rapid impact on patients is a hallmark of the RQ Bio discovery process, which stretches across four key disease areas of huge patient need, including COVID-19 and influenza.
  • Hugo Fry, CEO of RQ Bio, comments: "We're delighted that one of our discovered antibodies is now at the core of an innovative AstraZeneca investigational medicine reaching clinical trials.
  • This news confirms RQ Bio's smarter approach to antibody discovery works, fast.
  • The monoclonal antibody, discovered by RQ Bio, licensed and further developed by AstraZeneca (AZD3152), has excellent properties for clinical development, and was isolated from vaccinated volunteers after they had an Omicron-BA.1 infection.

Innovative Antibody Discovered by RQ Bio Enters Clinic as Part of Antibody Combination Within 12 Months of Discovery

Retrieved on: 
Wednesday, December 21, 2022
Antibody, Vaccination, Patient, AstraZeneca, Omicron, COVID-19, Risk, Safety, Death, Degenerative disease, Fry, Vaccine, Ministry of Women and Vulnerable Populations, Pre-exposure prophylaxis, Pharmaceutical industry

The potential for rapid impact on patients is a hallmark of the RQ Bio discovery process, which stretches across four key disease areas of huge patient need, including COVID-19 and influenza.

Key Points: 
  • The potential for rapid impact on patients is a hallmark of the RQ Bio discovery process, which stretches across four key disease areas of huge patient need, including COVID-19 and influenza.
  • Hugo Fry, CEO of RQ Bio, comments: "We're delighted that one of our discovered antibodies is now at the core of an innovative AstraZeneca investigational medicine reaching clinical trials.
  • This news confirms RQ Bio's smarter approach to antibody discovery works, fast.
  • The monoclonal antibody, discovered by RQ Bio, licensed and further developed by AstraZeneca (AZD3152), has excellent properties for clinical development, and was isolated from vaccinated volunteers after they had an Omicron-BA.1 infection.

CGTN: 'New Approaches': How China stepped up its COVID-19 treatments

Retrieved on: 
Wednesday, December 21, 2022
COVID-19 vaccine, National Health Commission, Death, University of Alabama at Birmingham School of Medicine, Vaccination, Antibody, School, RNA, Immune system, Tsinghua University, Nasal spray, Interview, Chinese Center for Disease Control and Prevention, Hospital, COVID-19, CDC, Nasal mucosa, Clinical trial, Immunity, China Media Group, Media Group, Vaccine, Pharmaceutical industry, Omicron

China has taken initiative in the development of COVID-19 drugs from three main approaches since the beginning of the pandemic.

Key Points: 
  • China has taken initiative in the development of COVID-19 drugs from three main approaches since the beginning of the pandemic.
  • The three strategies are inhibiting the virus' replication machinery, blocking the virus from entering a target cell and regulating human's immune system's overactive response.
  • That is, over 90 percent of people in China have received their full inoculation of COVID-19 vaccines – including a booster injection.
  • With continuous breakthrough in its vaccine development, China now has COVID-19 vaccines that can be given to people in ways of injection, inhaled and nasal spray.

CGTN: 'New Approaches': How China stepped up its COVID-19 treatments

Retrieved on: 
Wednesday, December 21, 2022
COVID-19 vaccine, National Health Commission, Death, University of Alabama at Birmingham School of Medicine, Vaccination, Antibody, School, RNA, Immune system, Tsinghua University, Nasal spray, Interview, Chinese Center for Disease Control and Prevention, Hospital, COVID-19, CDC, Nasal mucosa, Clinical trial, Immunity, China Media Group, Media Group, Vaccine, Pharmaceutical industry, Omicron

China has taken initiative in the development of COVID-19 drugs from three main approaches since the beginning of the pandemic.

Key Points: 
  • China has taken initiative in the development of COVID-19 drugs from three main approaches since the beginning of the pandemic.
  • The three strategies are inhibiting the virus' replication machinery, blocking the virus from entering a target cell and regulating human's immune system's overactive response.
  • That is, over 90 percent of people in China have received their full inoculation of COVID-19 vaccines – including a booster injection.
  • With continuous breakthrough in its vaccine development, China now has COVID-19 vaccines that can be given to people in ways of injection, inhaled and nasal spray.

CGTN: New Approaches : How China pushes COVID-19 vaccine R&D and inoculation

Retrieved on: 
Tuesday, December 20, 2022
Tao, COVID-19 vaccine, Vaccination, World Health Organization, Respiratory disease, Injection, WHO, Immune system, RNA transfection, COVID-19, NHC, Coronavirus, National Government, Epidemiology, Fortis Healthcare, Infection, Vaccine, National Health Commission, Ageing, Animal, Pharmaceutical industry, Aquaculture, Sinovac Biotech

It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.

Key Points: 
  • It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.
  • Three years into pandemic, China has approved 13 COVID-19 vaccines, including five inactivated vaccines, five recombinant protein vaccines, two viral vector vaccines and one live attenuated influenza vaccine.
  • China also has the most inoculation plans for its domestically developed COVID-19 vaccines that are based on inactivated virus, viral vector and recombinant protein.
  • China, with a population of 1.4 billion, has had administered nearly 3.46 billion doses of COVID-19 vaccines nationwide and provided over 2 billion doses worldwide.

CGTN: New Approaches : How China pushes COVID-19 vaccine R&D and inoculation

Retrieved on: 
Tuesday, December 20, 2022
Tao, COVID-19 vaccine, Vaccination, World Health Organization, Respiratory disease, Injection, WHO, Immune system, RNA transfection, COVID-19, NHC, Coronavirus, National Government, Epidemiology, Fortis Healthcare, Infection, Vaccine, National Health Commission, Ageing, Animal, Pharmaceutical industry, Aquaculture, Sinovac Biotech

It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.

Key Points: 
  • It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.
  • Three years into pandemic, China has approved 13 COVID-19 vaccines, including five inactivated vaccines, five recombinant protein vaccines, two viral vector vaccines and one live attenuated influenza vaccine.
  • China also has the most inoculation plans for its domestically developed COVID-19 vaccines that are based on inactivated virus, viral vector and recombinant protein.
  • China, with a population of 1.4 billion, has had administered nearly 3.46 billion doses of COVID-19 vaccines nationwide and provided over 2 billion doses worldwide.

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge

Retrieved on: 
Tuesday, December 20, 2022
President Trump, Human, Toxicity, Food, Vaccination, Wadsworth Center, University, NHP, COVID-19, Senior, FDA, Safety, Mouse, Death, News, RTA, Survival, Ricin, Doctor of Philosophy, University of Texas Southwestern Medical Center, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vaccine

The article titled "Serum antibody profiling identifies vaccine-induced correlates of protection against aerosolized ricin toxin in rhesus macaques" has been accepted for publication in the journal npj Vaccines (available here ).

Key Points: 
  • The article titled "Serum antibody profiling identifies vaccine-induced correlates of protection against aerosolized ricin toxin in rhesus macaques" has been accepted for publication in the journal npj Vaccines (available here ).
  • Formulated by Soligenix to have enhanced thermostability, RiVax® has demonstrated up to 100% protection in mice and NHPs subsequently exposed to lethal doses of ricin toxin either systemically or by aerosol.
  • Moreover, mice have been shown to be protected from ricin challenge at 10 times the lethal dose for at least 12 months post-vaccination.
  • With RiVax®, Soligenix is a world leader in the area of ricin toxin vaccine research.

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

Retrieved on: 
Tuesday, December 20, 2022
Spleen, Vaccination, Herpes simplex virus, Vaccine, Ganglion, Infection, CD8, RNA transfection, HSV-2, Mouse, News, Immunization, CD4, Relevant

The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.

Key Points: 
  • The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
  • In fact, the mRNA vaccine generates superior T cell responses.
  • Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
  • "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

Retrieved on: 
Tuesday, December 20, 2022
Spleen, Vaccination, Herpes simplex virus, Vaccine, Ganglion, Infection, CD8, RNA transfection, HSV-2, Mouse, News, Immunization, CD4, Relevant

The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.

Key Points: 
  • The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
  • In fact, the mRNA vaccine generates superior T cell responses.
  • Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
  • "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.

CGTN: New Approaches: Why China is easing its COVID-19 curbs now

Retrieved on: 
Tuesday, December 20, 2022
Death, World Health Organization, Vaccination, Severe acute respiratory syndrome coronavirus 2, Nature, Patient, Mutation, Respiratory disease, Laboratory, Hainan Medical University, Science Advances, COVID, National Institutes of Health, Routing protocol, Disease, University, Hong Kong residents, Alpha, COVID-19, Chinese Center for Disease Control and Prevention, Infection, Social mobility, Center for Infectious Disease Research and Policy, Virology, Mouse, Fudan University, Diagnosis, Economic development, Gamma, Sun, National Health Commission, Ageing, Virulence, Huashan Hospital, Animal, Pharmaceutical industry, Vaccine, Delta, Omicron

By November when China announced its new policies to relax a series of stringent measures meant to monitor and cut the spread of COVID-19, the country had reported over 5,000 deaths caused by this virus.

Key Points: 
  • By November when China announced its new policies to relax a series of stringent measures meant to monitor and cut the spread of COVID-19, the country had reported over 5,000 deaths caused by this virus.
  • The low death toll, out of a population of 1.4 billion, did not come easily.
  • As many countries tried and gave up stricter measures one after another in the past three years, China didn't follow.
  • Data showed that Omicron replicates to lower levels than the Delta in rhesus macaques, resulting in reduced clinical disease.